Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer.
Stevens‐Johnson syndrome
head and neck cancer
nivolumab
toxic epidermal necrolysis
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
11
2020
revised:
03
12
2020
accepted:
09
12
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
epublish
Résumé
This report is the first to document TEN caused by nivolumab treatment in head and neck cancer. We believe this article can contribute significantly in understanding the principles of nivolumab treatment in patients with head and neck cancer.
Identifiants
pubmed: 33598257
doi: 10.1002/ccr3.3695
pii: CCR33695
pmc: PMC7869372
doi:
Types de publication
Case Reports
Langues
eng
Pagination
848-852Informations de copyright
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
None declared.
Références
J Cutan Pathol. 2017 Apr;44(4):381-384
pubmed: 28000240
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Oncol Pharm Pract. 2019 Dec;25(8):2052-2055
pubmed: 30782092
Ann Oncol. 2018 Jan 1;29(1):283-284
pubmed: 29045532
J Invest Dermatol. 2013 May;133(5):1197-204
pubmed: 23389396
Clin Rev Allergy Immunol. 2018 Feb;54(1):147-176
pubmed: 29188475
JAAD Case Rep. 2018 Feb 23;4(3):229-231
pubmed: 29687056
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
J Invest Dermatol. 2006 Feb;126(2):272-6
pubmed: 16374461
J Am Acad Dermatol. 2007 Feb;56(2):181-200
pubmed: 17224365
Clin Pharmacol Ther. 2010 Jul;88(1):60-8
pubmed: 20375998